NCCN Guideline Updates and Choosing a First-Line ADC

The panel reviews how the metastatic TNBC treatment paradigm has evolved, tracing TROP2-directed ADCs from later-line use into the first-line setting. Panelists summarize the guideline-relevant data informing these changes and discuss how the clinical conversation has expanded to include selecting among available first-line options. The discussion offers a balanced, practical view of decision-making in the PD-L1–positive versus PD-L1–negative settings, considering efficacy alongside differing toxicity profiles, administration schedules, patient comorbidities, and preferences. Panelists also address patients who fall outside straightforward guideline scenarios, including those with poor performance status, prior ADC exposure in the early-stage setting, or contraindications to available agents, where clinical judgment and shared decision-making take precedence. This segment helps viewers connect emerging trial data to current guideline-supported practice and to the real-world considerations involved in individualizing first-line treatment.